Assembly Biosciences Selects Next-Generation CpAM Candidate for Advancement into Clinical Development
September 25, 2017
Assembly's first-generation CpAM, ABI-H0731, completed a Phase 1a study earlier this year and is currently being evaluated in HBV patients in a double blind, placebo-controlled, Phase 1b study. Assembly will present
additional data on its CpAM pipeline, including the ABI-H0731 Phase 1a study results, at the Annual Meeting of the
* Discovery on Target: Targeting HBV - Boston
Date: September 25, 2017
Panel: Targeting HBV Core Protein to Achieve Higher Cure Rates
Presenter: Richard Colonno, PhD., Chief Scientific Officer, HBV Program, Assembly Biosciences
A copy of Dr. Colonno's presentation will be available in
the Events and Presentations section of the Company's website later today, at www.assemblybio.com.
aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Assembly is developing a robust pipeline of product candidates in multiple disease indications. For more information, visit www.assemblybio.com.
The information in this press
release contains forward-looking statements regarding future events, including statements about the clinical and therapeutic potential of Assembly's development programs. Certain forward-looking statements may be identified by reference to a future period or periods or by use of forward-looking terminology such as "designed" or "developing." Assembly intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by Assembly are more fully detailed under the heading "Risk Factors" in Assembly's Annual Report on Form 10-K for the year ended
Assembly Biosciences, Inc.
News Provided by Acquire Media
« back to news page